Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

s trial will be presented by the lead investigator, Prof. Peter Stalmans, at the Euretina Conference on May 23, in Vienna. The third and fourth cohorts from this trial will be presented at major ophthalmic conferences in the second half of 2008.

- Results are expected from the Phase II MITI IV trial in mid 2008.

This Phase II trial is evaluating the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. Once these data from the study have been reviewed, a decision will be made on the future development plans for microplasmin in the treatment of acute stroke.

It is ThromboGenics' current intention that it will only move forward with the development of microplasmin for the treatment of stroke in conjunction with a partner. This intention is based on both the risks and cost associated with the development of new stroke therapies and the Company's desire to invest in its other attractive pipeline product candidates, such as microplasmin in the treatment of back of the eye diseases and TB-403.

TB-403

- Results from the initial Phase I trial of this novel anti-cancer agent in healthy volunteers are expected in the third quarter of 2008.

Following the successful completion of this initial Phase I study, ThromboGenics expects to begin a Phase Ib trial with TB-403 in end stage cancer patients in mid 2008. This study, which will recruit approximately 24 patients, is designed to provide both safety data on TB-403 when used in cancer patients and some early efficacy data on the product.

TB-402

- Top line results of the interaction studies to be announced by mid-2008.

TB-402 is being developed as an anti-coagulant for the prevention of deep vein thrombosis (DVT) after orthopaedic surgery and prevention of venous emboli in patients with atrial fibrillation. It is a novel human antibody that partially blocks Factor VIII, an essential blood clotting factor. The implicat
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 iLuv Creative ... of accessories for the mobile lifestyle, announces they are ... protect, and manage multiple iPad devices efficiently. Winner of ... the 2012 Good Design award, MultiCharger-X is revolutionizing the ... wherever it is deployed. , MultiCharger-X (iAD910) ...
(Date:5/22/2013)...   Oligomerix, Inc. , a privately held ... for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... financing, which includes both issuance of new convertible ... $2.8M in new investments in the Company.  Both ... Funding from the Series B ...
(Date:5/22/2013)... Mass. and NEW ORLEANS ... leader in the field of regenerative medicine, presented new ... economists from Analysis Group (a leading health economics consultancy) ... diabetic foot ulcers (DFU) and venous leg ulcers (VLU) ... The results of this research, which reveal annual costs ...
(Date:5/22/2013)... Ontario (PRWEB) May 22, 2013 ... advanced sound therapy for tinnitus treatment. AudioNotch is ... Hearing . With clinic locations in both British ... provider of audiology and hearing services. AudioNotch's tinnitus ... locations. , Upon entering a Destination Hearing clinic, ...
Breaking Biology Technology:iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2
... GAITHERSBURG, Md., Nov. 12 MaxCyte, Inc.,the pioneer ... it will be hosting a live discussion with ... assays for drug discovery.,The discussion is open to ... on,Thursday, November 13th from 2:00-3:00EST., One of ...
... Surgery Institute Is ... in Moscow, MOSCOW, Nov. 12 A Vermont eye ... he implanted the,Crystalens HD into a 49 year old Russian ... Randolph, Vermont performed the surgery at the,Ninth International Conference on ...
... Recommendations, BETHLEHEM, Pa., Nov. 12 ... Marketing, Infusion Systems Division and Helen,Chang, PharmD, ... Braun Medical,Inc. (B. Braun), a global leader ... B. Braun at the Institute for Safe ...
Cached Biology Technology:MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2Vermont Surgeon Implants First Accommodating Crystalens in Russia 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 3
(Date:5/21/2013)... a "patient monitoring" device attached to a whale entangled ... how fishing lines changed a whale,s diving and swimming ... ability to eat and migrate, depletes their energy as ... result in a slow death. , The scientists in ... Dtag to a two-year-old female North Atlantic right whale ...
(Date:5/21/2013)... Researchers at USC have found that a class of ... mice. , The drugs, known as "TSPO ligands," ... "We looked at the effects of TSPO ligand in ... stage, and in aged mice when pathology was quite ... Davis School of Gerontology. "TSPO ligand reduced measures of ...
(Date:5/21/2013)... health stores, phosphatidylserine is a natural food supplement ... improve cognition and slow memory loss, it,s a ... Now a team headed by Prof. Gil Ast ... Department of Human Molecular Genetics have ... of genes involved in degenerative brain disorders, including ...
Breaking Biology News(10 mins):Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3Drugs found to both prevent and treat Alzheimer's disease in mice 2Common food supplement fights degenerative brain disorders 2
... PLAINS, N.Y., FEB. 18, 2009 Regardless of where they ... receive mandated screening for many life-threatening disorders, a remarkable public ... new report issued today by the March of Dimes. ... that every baby be screened for 21 or more of ...
... TUCSON, AZCapillary mats are popular in the retail nursery ... mats provide automated irrigation to a variety of plants, ... Made with absorbent fabric lined with polyethylene film ... polyethylene or similar material, the mats help minimize evaporation ...
... , For more than 40 years, the prevailing explanation ... is called oxidative stress. This theory postulates that when molecules ... cells, they overwhelm the cells, ability to repair the damage ... "alternative" antioxidant therapies -- such as Vitamin E or CoQ10 ...
Cached Biology News:States expand newborn screening for life-threatening disorders 2States expand newborn screening for life-threatening disorders 3Capillary mats labor-saving, economical alternative to hand watering 2Forget the antioxidants? McGill researchers cast doubt on role of free radicals in aging 2
The optional fixed lens, 105 mm, is for use with the VersaDoc imaging systems for imaging small samples at high resolution....
The HQ505, 20 OptiGreen filter for the Molecular Imager FX is a band pass filter used for detection of Cy2 and FITC with 532 nm excitation....
... The ApopTag Red In Situ ... situ by the indirect TUNEL method, ... rhodamine fluorochrome. The kit provides indirect ... are analyzed using either fluorescence microscopy ...
... Model 175 tube gel cell is a ... for 2-D electrophoresis applications. The upper buffer ... tubes 9-23 cm long for isoelectric focusing ... buffer chamber and cooling core, lower buffer ...
Biology Products: